Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors. A significant proportion of cancers worldwide - estimated at 12% to 20%, is linked to infections, particu ...

A tumor “don’t‑eat‑me” shield also hides pro‑immune danger signals; new antibodies that unmask this hidden cue could make cancers more vulnerable to immune attack.

Immune system activation and activity is regulated through stimulatory or inhibitory ligand-receptor interactions collectively termed immune checkpoints. 1 Stimulatory interactions give the immune ...

ICIs combined with chemotherapy showed higher efficacy than bevacizumab in treating advanced driver gene–negative NS-NSCLC. The study reported improved PFS and OS for patients receiving ICIs compared ...

Liver cancer, particularly hepatocellular carcinoma (HCC), presents major clinical challenges due to the multifaceted nature of its tumor immune ...

Virus-associated cancers are a significant and persistent global health challenge, providing unique insight into the relationship between chronic infection ...

Please provide your email address to receive an email when new articles are posted on . The consortium has enrolled approximately 1,000 patients with immune-related adverse events from checkpoint ...

ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today announced that Phase 1b data for IBC-Ab002, a newly engineered ...

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with ...

We conducted a prospective study of patients with solid tumors who received pembrolizumab or atezolizumab at the National Institute of Oncology, Rabat from July 2018 to December 2023. We identified ...

Feasibility Study for Using Large Language Models to Identify Goals-of-Care Documentation at Scale in Patients With Advanced Cancer A retrospective analysis of 3,626 patients treated with ICIs for ...